To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 127
Updated:3/17/2019
Start Date:February 21, 2018
End Date:January 20, 2021
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in
combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related
protein kinase (AZD6738) and olaparib monotherapy versus olaparib in combination with an
inhibitor of WEE1 (AZD1775) in second or third line setting in patients with Triple-negative
breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour
mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment
arms are olaparib monotherapy, olaparib+AZD6738 and olaparib+AZD1775. The study subject
population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different
schedules of administration of each of the treatment options as well as their different
toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1
consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with
TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the
option of consenting to the main part of the study within the 28-day screening period.
Approximately 450 patients will be randomised (using randomisation ratio 1:1:1) to 3
treatment arms.

This is a prospective, open label, randomised, multi-centre Phase 2 study that will assess
the efficacy and safety of olaparib monotherapy versus olaparib in combination with an
inhibitor of ATR (AZD6738) and olaparib monotherapy versus olaparib in combination with an
inhibitor of WEE1 (AZD1775) in second or third line setting in patients with TNBC
prospectively stratified by presence/absence of qualifying tumour mutation in genes involved
in the HRR pathway.

Eligible patients will be randomised by a ratio 1:1:1 to treatment Arm 1: olaparib continuous
in a 28-day cycle, Arm 2: AZD6738 Days 1-7 with olaparib continuous in a 28-day cycle or Arm
3: AZD1775 Days 1-3 and 8-10 with olaparib continuous in a 21-day cycle. The study subject
population will be divided into Stratum A (patients with mutations in BRCA1 or BRCA2 (Breast
cancer susceptible gene mutation (BRCAm)), Stratum B (patients with mutations in any of the
other genes involved in the HRR pathway and no mutation in BRCA1 and no mutation in BRCA2),
and Stratum C (patients with no detected tumour mutations in any of the HRR genes). Within
each stratum A, B and C, there will be further stratification by whether the patient received
prior platinum-based therapy.

In the olaparib monotherapy treatment arm as well as in the AZD6738+olaparib treatment arm,
patients will be administered olaparib bd at 300 mg continuously. Two (2) 150 mg olaparib
tablets will be taken at the same time each day, approximately 12 hours apart with one glass
of water (approximately 250 mL). In the AZD1775+olaparib treatment arm, patients will be
given olaparib 200 mg bd (2 x 100 mg tablets twice a day) and AZD1775 150 mg bd from Day 1 to
Day 3 (inclusive) and Day 8 to Day 10 (inclusive) of every 21-day cycle. AZD6738 will be
supplied as 20 mg, 80 mg, or 100 mg film coated tablets. Patients will be administered
AZD6738 od at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle. A total of 160 mg
of AZD6738 tablets will be taken at the same time on each day of dosing with approximately
250 mL of water. AZD1775 will be supplied as capsules containing 25 mg, 50 mg, 75 mg, 100 mg,
or 200 mg of drug substance. AZD1775 will be taken with approximately 250 mL of water
approximately 2 hours before or 2 hours after food. Olaparib, AZD6738 and AZD1775 will be
provided by AstraZeneca.

Primary outcome measures (progression free survival [PFS]) will be analysed for the 3 patient
populations BRCAm, Non BRCAm HRRm (Homologous Recombination Repair gene mutation) and Non
HRRm. Secondary outcome measures will be analysed in 2 patient populations HRRm and All for
PFS, Objective response rate (ORR) and overall survival (OS) will be analysed in all 5
patient populations. DoR, and tumour change will be analysed in BRCAm, Non BRCAm HRRm, and
Non HRRm patient populations. Tumour and germline mutation status will be analysed only in
the all patient population. PK outcome measures will be analysed only in the all patient
population. Blinded Independent Central Review (BICR) of radiological imaging data will be
carried out using RECIST version 1.1 and Investigator assessments will also be analysed for
sensitivity purposes.

Pertinent Inclusion criteria:

1. Informed consent prior to any study specific procedures.

2. Male or female ≥18 years of age.

3. Progressive cancer at the time of study entry.

4. Histologically or cytologically confirmed TNBC with evidence of metastatic disease and
HER2 negative as per ASCO-CAP HER2 guideline recommendations 2013.

5. Patients must have received at least 1 and no more than 2 prior lines of treatment for
metastatic disease with an anthracycline (eg, doxorubicin, epirubicin) and/or a taxane
(eg, paclitaxel, docetaxel) unless contraindicated, in either the neo-adjuvant,
adjuvant or metastatic setting.

6. Confirmed presence of qualifying HRR mutation or absence of any HRR mutation in tumour
tissue by the Lynparza HRR assay.

7. At least one measurable lesion that can be accurately assessed at baseline by computed
tomography (CT) (magnetic resonance imaging [MRI] where CT is contraindicated) and is
suitable for repeated assessment as per RECIST 1.1.

8. Patients must have normal organ and bone marrow function measured within 28 days prior
to randomization (defined in the protocol).

9. ECOG PS 0-1 within 28 days of randomisation.

10. Postmenopausal or evidence of non-childbearing status for women of childbearing
potential (contraception restrictions apply to participants and their partners).

13. Patient is willing to comply with the protocol requirements. 14. Life expectancy of ≥16
weeks.

Pertinent Exclusion criteria:

1. Cytotoxic chemotherapy, hormonal or non hormonal targeted therapy within 21 days of
Cycle 1 Day 1 is not permitted. Palliative radiotherapy must have been completed 21 or
more days before Cycle 1 Day 1. The patient can receive a stable dose of
bisphosphonates or denosumab for bone metastases, before and during the study as long
as these were started at least 5 days prior to study treatment.

2. More than 2 prior lines of cytotoxic chemotherapy for metastatic disease (prior
treatments with hormonal, non-hormonal, biologics or the combination of an aromatase
inhibitor and everolimus are not counted as a prior line of therapy).

3. Previous randomisation in the present study.

4. Previous treatment with a PARP inhibitor (including olaparib) or other DDR inhibitor
(unless less than 3 weeks duration and at least 12 months has elapsed between the last
dose and randomization).

5. Exposure to a small molecule IP within 30 days or 5 half-lives (whichever is longer)
prior to randomisation. The minimum washout period for immunotherapy shall be 42 days.

6. Patients with second primary cancer (exceptions defined in the protocol).

7. Mean resting corrected QTc interval using the Fridericia formula (QTcF) >470
msec/female patients and >450 msec for male patients (as calculated per institutional
standards) or congenital long QT syndrome.

8. Any of the following cardiac diseases currently or within the last 6 months: unstable
angina pectoris, congestive heart failure ≥ Class 2 as defined by the New York Heart
Association, acute myocardial infarction, conduction abnormality not controlled with
pacemaker or medication (patients with a conduction abnormality controlled with
pacemaker or medication at the time of screening are eligible), significant
ventricular or supraventricular arrhythmias (patients with chronic rate-controlled
atrial fibrillation in the absence of other cardiac abnormalities are eligible).

9. Concomitant use of known strong or moderate cytochrome P (CYP) 3A inhibitors, strong
or moderate CYP3A inducers, or sensitive CYP3A4 substrates or CYp3A4 substrates with a
narrow therapeutic index.

10. Persistent toxicities (≥ CTCAE grade 2) caused by previous cancer therapy, excluding
alopecia and CTCAE grade 2 peripheral neuropathy.

11. Major surgery within 2 weeks of starting study treatment: patients must have recovered
from any effects of any major surgery.

12. Immunocompromised patients, eg, human immunodeficiency virus (HIV).

13. Patients with known active hepatitis (ie, hepatitis B or C).

14. Patients considered a poor medical risk due to a serious, uncontrolled medical
disorder, non malignant systemic disease or active, uncontrolled infection.

15. Patients with symptomatic uncontrolled brain metastases.

16. Patients unable to swallow orally administered medication and patients with
gastrointestinal disorders likely to interfere with absorption of the study
medication.

17. Patients with a known hypersensitivity to olaparib, AZD1775, AZD6738, or any of the
excipients of the products.

18. Pregnant or breast feeding women.
We found this trial at
25
sites
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Brasschaat,
Click here to add this to my saved trials
?
mi
from
Brick, NJ
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
East Setauket, NY
Click here to add this to my saved trials
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
?
mi
from
Hazard, KY
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
Kettering, OH
Click here to add this to my saved trials
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Munster, IN
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
Olympia, WA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
?
mi
from
Worcester, MA
Click here to add this to my saved trials